Next New Releases from NCBI BookshelfBlinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].Blinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].
